Compare RVLV & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RVLV | MLTX |
|---|---|---|
| Founded | 2003 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.7B |
| IPO Year | 2018 | 2020 |
| Metric | RVLV | MLTX |
|---|---|---|
| Price | $24.79 | $19.63 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 12 |
| Target Price | ★ $29.73 | $27.50 |
| AVG Volume (30 Days) | 802.9K | ★ 1.5M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 24.64 | N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $1,225,682,000.00 | N/A |
| Revenue This Year | $10.96 | N/A |
| Revenue Next Year | $8.01 | N/A |
| P/E Ratio | $127.10 | ★ N/A |
| Revenue Growth | ★ 8.48 | N/A |
| 52 Week Low | $17.35 | $5.95 |
| 52 Week High | $31.68 | $62.75 |
| Indicator | RVLV | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 64.83 | 52.93 |
| Support Level | $21.55 | $15.89 |
| Resistance Level | $26.65 | $21.14 |
| Average True Range (ATR) | 0.92 | 0.91 |
| MACD | 0.20 | -0.07 |
| Stochastic Oscillator | 77.58 | 46.10 |
Revolve Group Inc is an emerging e-commerce retailer, selling women's dresses, handbags, shoes, beauty products, and incidentals across its marketplace properties, Revolve and FWRD. The platform is built to suit the "next-generation customer," emphasizing mobile commerce, influencer marketing, and occupying an aspirational but attainable luxury niche. With $1.1 billion in 2024 net sales, the firm sits just outside the top 30 apparel retailers (by sales) in the U.S, but has consistently generated robust top-line growth as the industry continues to favor digital channels. Revolve generates approximately 18% of sales from private-label offerings, while focusing on building an inventory of distinctive products from emerging fashion brands with less than $10 million in annual sales.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.